Who is sponsoring NCT04166721?

NCT04166721 is sponsored by Royal Marsden NHS Foundation Trust.

What drugs are being tested in NCT04166721?

Interventions in NCT04166721: Atezolizumab.

What condition does NCT04166721 study?

NCT04166721 studies Metastatic Esophageal Cancer, Metastatic Gastric Cancer.

Is NCT04166721 still recruiting?

NCT04166721 is currently active, enrolled. Last updated 6 April 2025.

Last reviewed 2025-04-06 · How we verify

NCT04166721

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Active, enrolled Phase 1, PHASE2 Last updated 6 April 2025

What this trial tests

Phase 1, PHASE2 trial testing Atezolizumab in Metastatic Esophageal Cancer in 52 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

11 February 2020

Primary endpoint
30 March 2025

31 December 2025

Quick facts

Lead sponsor	Royal Marsden NHS Foundation Trust
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	52
Start date	11 February 2020
Primary completion	30 March 2025
Estimated completion	31 December 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Metastatic Esophageal Cancer — all drugs for Metastatic Esophageal Cancer →
Metastatic Gastric Cancer — all drugs for Metastatic Gastric Cancer →

Sponsor

Royal Marsden NHS Foundation Trust

Who can join

18 and older, any sex, with Metastatic Esophageal Cancer or Metastatic Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicentre open-label non-randomised, Single Stage Ahern Design (with a 3+3 design for the safety run-in) phase II clinical trial of DKN-01 plus atezolizumab in patients with advanced unresectable or metastatic OGA who have progressed following chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.
Czajka-Francuz P, Prendes MJ, Mankan A, Quintana Á, et al · · 2023 · cited 46× · PMID 37427115 · DOI 10.3389/fonc.2023.1200646
Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers.
Muto S, Enta A, Maruya Y, Inomata S, et al · · 2023 · cited 44× · PMID 36672698 · DOI 10.3390/biomedicines11010190
Carboxylesterase Notum Is a Druggable Target to Modulate Wnt Signaling.
Bayle ED, Svensson F, Atkinson BN, Steadman D, et al · · 2021 · cited 36× · PMID 33783220 · DOI 10.1021/acs.jmedchem.0c01974
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy.
Chen J, Duan Y, Che J, Zhu J. · · 2024 · cited 34× · PMID 39051512 · DOI 10.1002/cac2.12596
The Relevance of Transcription Factors in Gastric and Colorectal Cancer Stem Cells Identification and Eradication.
Pádua D, Figueira P, Ribeiro I, Almeida R, et al · · 2020 · cited 34× · PMID 32626705 · DOI 10.3389/fcell.2020.00442
Wnt/β-catenin mediated signaling pathways in cancer: recent advances, and applications in cancer therapy.
Wu X, Que H, Li Q, Wei X. · · 2025 · cited 33× · PMID 40495229 · DOI 10.1186/s12943-025-02363-1
Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views.
Kim MJ, Huang Y, Park JI. · · 2020 · cited 30× · PMID 33291655 · DOI 10.3390/cancers12123638
Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.
Seeber A, Battaglin F, Zimmer K, Kocher F, et al · · 2022 · cited 27× · PMID 35254413 · DOI 10.1158/1078-0432.ccr-21-3018

Verify or expand the search:

Other trials of Atezolizumab

Trials testing the same drug.

NCT07388524 — Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer · Phase 3 · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07461675 — Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resec · Phase 3 · not yet recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other recruiting trials for Metastatic Esophageal Cancer

Currently open trials in the same condition.

NCT06251973 — A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophage · Phase 2 · recruiting

Other Royal Marsden NHS Foundation Trust trials

Trials by the same sponsor.

NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04166721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
Last refreshed: 6 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04166721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing